

RESOLUTIONS PASSED AT THE ANNUAL GENERAL MEETING HELD ON 29 SEPTEMBER 2020

Capitalised terms used herein, unless otherwise defined, shall have the definitions ascribed to them in the annual report of the Company for the financial year ended 31 May 2020 (“AR2020”) and the appendix to the AR2020 which were despatched to shareholders of HC Surgical Specialists Limited (the “Company”) on 7 September 2020.

The Board of Directors of the Company is pleased to announce that, pursuant to Rule 704(15) of the Singapore Exchange Securities Trading Limited (“SGX-ST”) Listing Manual Section B: Rules of Catalist (the “Catalist Rules”), all of the resolutions set out in the Notice of the Annual General Meeting (“AGM”) dated 7 September 2020 were duly passed by way of poll, at the AGM held on 29 September 2020, by way of electronic means.

(a) The results of the poll on the resolutions put to the vote at the AGM are as follows:-

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against		
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	
Ordinary Business						
1	Re-election of Dr. Heah Sieu Min as Director of the Company ⁽¹⁾	108,436,333	108,436,333	100.00	0	0.00
2	Re-election of Mr. Ooi Seng Soon as Director of the Company ⁽²⁾	108,436,333	108,436,333	100.00	0	0.00
3	Directors’ Fees of S\$100,000/- for the financial year ended 31 May 2020	108,436,333	108,436,333	100.00	0	0.00
4	Declaration of final dividend (tax-exempt one-tier) of S\$0.007 per ordinary share for the financial year ended 31 May 2020	108,436,333	108,436,333	100.00	0	0.00

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against		
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	
Ordinary Business						
5	Re-appointment of Messrs BDO LLP as auditors of the Company	108,436,333	108,436,333	100.00	0	0.00
Special Business						
6	Authority to issue ordinary shares	108,436,333	108,436,333	100.00	0	0.00
7	Authority to issue shares under the HCSS Performance Share Plan	108,436,333	108,436,333	100.00	0	0.00
8	Authority to issue shares under the HCSS Employee Share Option Scheme	108,436,333	108,436,333	100.00	0	0.00
9	Proposed Renewal of the Share Buy-Back Mandate	44,447,353	44,447,353	100.00	0	0.00

Notes:

(1) Dr. Heah Sieu Min, who was re-elected as a Director under Resolution 1, remains as the Executive Director and Chief Executive Officer of the Company.

(2) Mr. Ooi Seng Soon, who was re-elected as a Director under Resolution 2, remains as the Independent Non-Executive Director as well as the chairman of the Audit Committee and member of the Nominating Committee and Remuneration Committee of the Company. He is considered independent for the purpose of Rule 704(7) of the Catalist Rules.

(b) Details of the party who had abstained from voting on Resolution 9 and his shareholdings is as follows:-

<u>Name</u>	<u>Number of shares held</u>
1. Dr. Heah Sieu Min	63,988,980

(c) Name of firm appointed as Scrutineer:

Entrust Advisory Pte. Ltd. was appointed as the scrutineer for the AGM.

By Order of the Board

Dr. Heah Sieu Min
Executive Director and Chief Executive Officer

Date: 29 September 2020

About HC Surgical Specialists Limited

HC Surgical Specialists Limited (the “Company”) was incorporated on 1 September 2015 in Singapore and listed on Catalist of the Singapore Exchange Securities Trading Limited on 3 November 2016. The Company, its subsidiaries and associated company are a medical services group primarily engaged in the provision of endoscopic procedures, including gastroscopies and colonoscopies, and general surgery services with a focus on colorectal procedures across a network of 18 clinics located throughout Singapore.

This announcement has been prepared by the Company and reviewed by the Company’s sponsor, Novus Corporate Finance Pte. Ltd. (the “Sponsor”), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 9 Raffles Place, #17-05 Republic Plaza Tower 1, Singapore 048619, telephone (65) 6950 2188.